R2 REVLIMID/RITUXIMAB holds 1 USPTO trademark filings across 0 NICE classes. The largest concentration is in Class 5 (Pharmaceuticals) with 1 filings. The WikiTrademarks Expansion Score is 3/100, low — the brand is focused on defending its existing categories rather than expanding.
USPTO data refreshed July 12, 2026
Own this brand? Claim the profile to add your logo, story, and website.
Sign in to claimHow is R2 REVLIMID/RITUXIMAB filing trademarks, and where is the portfolio expanding?
Filing Velocity (24 Months)
Nice Class Distribution
Activity Timeline
No activity recorded yet.
Recent Filings
| Serial No. | Mark | Filing Date | Status | Classes | Owner |
|---|---|---|---|---|---|
| 88655362 | R2 REVLIMID/RITUXIMAB | Oct 15, 2019 | Pending | 005 Pharmaceuticals 044 Medical & Beauty Services | Celgene Corporation |
Weekly visibility reports showing how ChatGPT mentions R2 REVLIMID/RITUXIMAB, where you rank in the answer, the sentiment of the mention, and which sources ChatGPT cites.
FAQ: R2 REVLIMID/RITUXIMAB trademark portfolio
What trademarks does R2 REVLIMID/RITUXIMAB hold?
R2 REVLIMID/RITUXIMAB holds 1 USPTO trademark filings across 0 NICE classes. The largest concentration is in Class 5 (Pharmaceuticals), Class 44 (Medical & Beauty Services). The most recent filings are registered to Celgene Corporation.
How many trademarks does R2 REVLIMID/RITUXIMAB have at the USPTO?
WikiTrademarks tracks 1 USPTO trademark filings attributed to R2 REVLIMID/RITUXIMAB. The brand has been actively filing since October 2019. The count updates daily as new filings are indexed from the USPTO bulk data feed.
In which NICE classes does R2 REVLIMID/RITUXIMAB file most often?
R2 REVLIMID/RITUXIMAB's most active class is NICE Class 5 (Pharmaceuticals), with 1 filings. The full distribution across all 0 classes is shown in the Nice Class Distribution panel on this page.
Who owns the R2 REVLIMID/RITUXIMAB trademark?
The most recent filings under the R2 REVLIMID/RITUXIMAB mark are registered to Celgene Corporation. Trademark ownership can shift through assignments — see the Ownership & Assignment History section on this page for the full chain of title.
Is R2 REVLIMID/RITUXIMAB expanding into new categories?
The current WikiTrademarks Expansion Score for R2 REVLIMID/RITUXIMAB is 3 out of 100, which is low — the brand is focused on defending its existing categories rather than expanding. The score combines NICE class breadth, filing velocity, and the rate of cross-class movement from the brand's filing history.
How can I track new R2 REVLIMID/RITUXIMAB trademark filings?
Click the Watch Brand button at the top of this page to add R2 REVLIMID/RITUXIMAB to your Watchlist. New filings show up on your WikiTrademarks dashboard within 24 to 48 hours of being public, alongside any class expansions, status changes, or assignment events.
More on this portfolio: Compare R2 REVLIMID/RITUXIMAB to another owner · Browse all NICE classes · Most valuable brands
Community notes
0 notesShare what you know about R2 REVLIMID/RITUXIMAB and help the next person researching it.